Navigation Links
Mederi Therapeutics Closes Funding of $18.5 Million

GREENWICH, Conn., Dec. 23, 2013 /PRNewswire/ -- Mederi Therapeutics Inc. announced today the closing on $18.5 million, comprised of Series B preferred stock and venture debt. Participating in this round were Acadia Woods Partners, LLC, Respiratory Diagnostics Inc., a subsidiary of Bio-Rad Laboratories, Inc., as well as a group of high net worth equity investors. Venture debt was provided by Horizon Technology Finance. The funds will be used to support and expand on the rapidly growing use of Mederi's Stretta therapy for Gastroesophageal Reflux Disease (GERD) and Secca therapy for Bowel Incontinence.

The overwhelming body of clinical data supporting Stretta's safety, efficacy and durability of effect has led to Mederi's rapid expansion. "Many device start-up companies launch with large sales forces and deep marketing budgets before gaining traction with clinical data and reimbursement. Mederi has strategically built sales and marketing as we gained such traction," said Will Rutan, CEO of Mederi. "This conservative approach has paid off, resulting in expanding insurance coverage domestically and abroad, significant growth in 2013, and product availability in almost 40 countries on a relatively small amount of investor capital."

"We are very pleased to have the support of all of our original investors plus a select new group, as well as the growing support of the medical community in our efforts to mainstream these safe and effective, minimally invasive therapies," continued Rutan.

The Value of a Safe, Effective, Low Cost Option
Mederi's radiofrequency treatments provide value to payers, providers and patients by offering safe, effective, durable and low-cost therapies.  Approximately 40 million Americans suffer from GERD, and 30% of those don't fully respond to medications. Stretta therapy for GERD is backed by more than 32 clinical studies showing up to 10 years of safe, durable symptom relief. These funds will allow Mederi to broaden Stretta's reach within the medical and patient communities, as it clearly addresses an unmet need in the treatment of GERD by providing an alternative to lifelong medications or surgery.

Mederi Therapeutics manufactures and markets innovative medical devices that use radiofrequency energy to treat diseases of the digestive system, and holds over 80 patents in this technology. Mederi therapies — Stretta, for GERD and Secca, for Bowel Incontinence — have demonstrated clinical effectiveness in numerous studies; they are outpatient, minimally invasive and promote rapid recovery. Mederi is located in Greenwich, Connecticut. For more information visit

Contact: Sheila Doyle, 203-930-9980,

SOURCE Mederi Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. SkilaMederi and Qforma Announce Merger
2. SkilaMederi Names Ray Joske as Chief Commercial Officer
3. Aratana Therapeutics Provides 2013 Development Update
4. 2013 Report on the International Pain Management Therapeutics Market - Includes Forecast to 2018
5. Spark Therapeutics to Present at 32nd Annual J.P. Morgan Healthcare Conference
6. Updated Financial Standings, Company Announcements, and Customer-Centered Suggestions - Research Report on Perrigo, Thermo Fisher, DaVita, United Therapeutics, and Keryx Biopharmaceuticals
7. Sorrento Therapeutics Completes Acquisition of Concortis Biosystems
8. Portfolio Expansions, Product Data, and Announcements by Healthcare Companies - Research Report on Life Technologies, OncoMed, Halozyme Therapeutics, Infinity, and PTC Therapeutics
9. Circuit Therapeutics and Boehringer Ingelheim announce signature of a research partnership agreement to discover new approaches to treating psychiatric disorders
10. Cell Therapeutics Receives Remaining $5 million Under Existing Loan Financing Agreement
11. Halozyme Therapeutics Announces Executive Transitions
Post Your Comments:
(Date:11/29/2015)... 2015  The GE Health Cloud 1 was unveiled ... North America (RSNA) meeting in ... the new cloud ecosystem and its applications will connect radiologists ... and multidisciplinary teams – both inside and outside the hospital ... of GE. "As the digital industrial leader, we are betting ...
(Date:11/27/2015)... November 27, 2015 --> ... to go online. The potential to save costs, improve ... and far from fully exploited as yet. Here, particular ... records, either via mobile tablet or directly at the ... ) -->      (Photo: ...
(Date:11/27/2015)... ) ... "2016 Global Tumor Marker Testing Market: Supplier ... Segment Forecasts, Innovative Technologies, Instrumentation Review, Competitive ... offering. --> ) has ... Global Tumor Marker Testing Market: Supplier Shares ...
Breaking Medicine Technology:
(Date:11/27/2015)... Denver, CO (PRWEB) , ... November 27, 2015 , ... ... U.S. cities are not changing the way that they are handling security in light ... increasing police and security presence in an attempt to stop an attack from reaching ...
(Date:11/27/2015)... ... ... A team of Swiss doctors has released a report on mesothelioma relapse and ... findings on the website. Click here to read the details now. ... were treated with chemotherapy followed by EPP surgery. Among the 106 patients who relapsed, ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When I was traveling, I ... Hillside, N.J. "Many people catch diseases simply from sitting on such dirty toilet ... protected from germs." , He developed the patent-pending QUDRATECS to eliminate the need ...
(Date:11/27/2015)... ... November 27, 2015 , ... The print ... USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation ... is distributed nationally, through a vast social media strategy and across a network ...
(Date:11/27/2015)... ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, ... Table 1-1 ). More than 3.7 billion people under the age of 50 – ... according to WHO's first global estimates of HSV-1 infection . , "The data shocks ...
Breaking Medicine News(10 mins):